Recent Company News

• 09:04 AM ET Jun 25, 2026
  

  UCB notes its therapies gain broad coverage across Canada for the treatment of Generalized myasthenia Gravis (gMG) (€254.30, -0.70)

• 01:27 AM ET Jun 17, 2026
  

  UCB completes acquisition of Candid Therapeutics (€250.00, 0.00)

• 05:30 PM ET Jun 15, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:51 AM ET Jun 15, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:13 AM ET Jun 15, 2026
  

  Autos, travel, construction and banks the best performers; energy and defensives the biggest laggards:

• 04:27 AM ET Jun 15, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:50 AM ET Jun 15, 2026
  

  UCB downgraded to equal weight from overweight at Barclays (€274.90, 0.00)

• 09:04 AM ET Jun 09, 2026
  

  UCB notes BIMZELX (bimekizumab injection) receives positive reimbursement recommendation from Canada's drug agency for Hidradenitis Suppurativa (€260.80, -0.20)

• 09:19 AM ET Jun 08, 2026
  

  Transcript Intelligence: UCB Capital Markets Day

• 01:02 AM ET Jun 05, 2026
  

  UCB announces new EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels (€259.50, 0.00)